SEP 11, 2018 08:21 PM PDT

Potential Non-Antibiotic Drug For Tuberculosis

WRITTEN BY: Nouran Amin

Credit: Image via Homeopathy Plus (homeopathyplus.com)

After 10 years of research, scientists at the University of Manchester have created the first non-antibiotic drug that can successfully treat tuberculosis (TB) in animal models. The research, which was funded by the Medical Research Council, was published in the Journal of Medicinal Chemistry. The scientists hope that the developed drug will enter clinical trials within the next three to four years.

The drug works by targeting the Mycobacterium tuberculosis’ defense system rather than attacking the bacterium itself, possibly taking out the common antibiotic-resistant strain. Even though 100 years earlier, a vaccine was created for TB, still today one in three people across the globe are thought to be infected. Roughly 1.7 million worldwide die annually from TB, however, about 7.3 million of those diagnosed with TB were treated in 2018.

The infectious disease is most prevalent in Africa, India, and China. However, it has been recently on the rise in the UK with London often labeled as the “TB capital of Europe”. Those diagnosed with TB often are prescribed a series of strong antibiotics over the course of 6 to 8 months while withstanding adverse side effects including a 20% risk of the disease returning.

Now, the developed drug was proven effective in rodents at Rutgers University. "The fact that the animal studies showed our compound, which doesn't kill the bacteria directly, resulted in a significant reduction in the bacterial burden is remarkable,” explains project leader Professor Lydia Tabernero. “For more than 60 years, the only weapon doctors have been able to use against TB is antibiotics. But resistance is becoming an increasingly worrying problem and the prolonged treatment is difficult and distressing for patients. And with current treatments, there's no guarantee the disease will be eliminated: antibiotics do not clear the infection and the risk of being infected with drug-resistant bacteria is very high. But by disabling this clandestine bacteria's defenses we're thrilled to find a way that enhances the chances of the body's immune system to do its job, and thus eliminates the pathogen."

The bacterium responsible for tuberculosis produces molecules known as Virulence Factors which help inhibit the immune response to the infection. One Virulence Factor that was identified is called MptpB. MptpB is a drug suitable target because when inhibited, it allows the white blood cells (leukocytes) to kill the Mycobacterium effectively. "The great thing about MptpB is that there's nothing similar in humans -- so our compound which blocks it is not toxic to the human cells,” explains Tabernero. "Because the bacteria hasn't been threatened directly, it is less likely to develop resistance against this new agent, and this will be a major advantage over current antibiotics, for which bacteria had already become resistant. TB is an amazingly difficult disease to treat so we feel this is a significant breakthrough. The next stage of our research is to optimize further the chemical compound, but we hope Clinical trials are up to four years away."

To learn more about Tuberculosis, watch the video below!

Source: Journal of Medicinal Chemistry, University of Manchester

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUN 20, 2018
Drug Discovery
JUN 20, 2018
New Drug 'Moxidectin' for River Blindness
A new treatment to help eliminate a neglected tropical disease was developed thanks in part to an incentive program devised by researchers at Duke Universi...
JUN 27, 2018
Drug Discovery
JUN 27, 2018
Efficacy of The 24 Hour Killing Flu Drug 'Xofluza' Examined
Xofluza, the recent 24-hour killing flu drug that was developed by the Japanese pharmaceutical company Shionogi and approved for clinical use in Japan, is ...
JUL 04, 2018
Drug Discovery
JUL 04, 2018
Increased Dose of Drug 'Rifampin' Effective in Eliminating Tuberculosis Bacterium
According to a randomized controlled trial, a TB drug by the name ‘Rifampin’ was seen to effectively kill TB bacteria in sputum cultures when a...
AUG 21, 2018
Drug Discovery
AUG 21, 2018
Genetic Regulators of Regeneration Bring Hope for Drug Discovery
Portions of DNA that do not seem to have a function are referred to as “junk”. Now, according to a study published in Regenerative Medicine, re...
SEP 04, 2018
Drug Discovery
SEP 04, 2018
Cellular Mechanism Inspires Bone-Forming Drugs
There exists a certain amount of therapeutic drugs that treat osteoporosis by promoting bone formation in comparison to only a few drugs used to suppress b...
SEP 08, 2018
Drug Discovery
SEP 08, 2018
Protein Associated With ALS Inspires Drug Treatments
Neurodegenerative diseases, such as degenerative ataxia or amyotrophic lateral sclerosis (ALS), will progressively cause an affected individual to develop ...
Loading Comments...